Allink Biotherapeutics, Inc. has successfully completed $47 million extension rounds of Series A, accelerating its clinical development efforts for unique antibody-drug conjugates.

Allink Biotherapeutics has completed a $47 million extension round of Series A funding to advance clinical programs and innovative platforms, enhancing their ADC technology development.

Allink Biotherapeutics announces successful completion of a $47 million Series A extension to accelerate the development of antibody-drug conjugates and other innovative therapies.

Allink Biotherapeutics has successfully raised $47 million in additional Series A funding led by Legend Capital and Meituan Long-Z Investment, aiming to escalate their clinical programs.

Allink Biotherapeutics has successfully raised $42 million in Series A funding to further develop bispecific antibodies and ADCs in global markets.

Allink Biotherapeutics has successfully raised $42 million in Series A funding, marking a significant step in advancing its bispecific antibody and ADC programs.